Skip to main navigation
Skip to search
Skip to main content
Albert Einstein College of Medicine Home
Home
Faculty
Departments
Grants
Publications
Prizes
Search by expertise, name or affiliation
Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study
BEIJERINCK Investigators
Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
34
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
evolocumab
100%
Double-Blind Method
58%
Dyslipidemias
58%
HIV
41%
Hydroxymethylglutaryl-CoA Reductase Inhibitors
28%
LDL Cholesterol
26%
Placebos
16%
Lipids
11%
Lipoproteins
11%
Cardiovascular Diseases
8%
lipoprotein cholesterol
7%
Lipoprotein(a)
7%
Apolipoproteins B
6%
Research Subjects
5%
Hypercholesterolemia
5%
Contraindications
5%
Therapeutics
4%
Confidence Intervals
3%
Safety
3%
Incidence
2%